Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension


Topouzis et al. Eur J Ophthalmol 2021;31:103–111

A phase 4 double-blind trial to evaluate the additive effect of brinzolamide 1% / brimonidine 0.2% fixed-dose combination on intraocular pressure in patients with open-angle glaucoma or ocular hypertension



Aim: To evaluate the additive IOP-lowering effect of twice-daily brinzolamide 1% / brimonidine 0.2% fixed dose combination (BBFC) as adjunct to PGA in people with open angle glaucoma in whom PGA alone is insufficient.

Study design



Conclusion

Twice-daily BBFC in addition to PGA may be a suitable treatment option for patients with open-angle glaucoma or ocular hypertension for whom PGA monotherapy is insufficient in reducing IOP. The safety profile of BBFC + PGA was consistent with the known safety profiles of brinzolamide, brimonidine, and PGAs.

Abbreviations: BBFC, brinzolamide 1%/brimonidine 0.2% fixed dose combination; CCT, central corneal thickness; IOP, intraocular pressure; OAG, open angle glaucoma; OH, ocular hypertension; PGA, prostaglandin analogue

Topouzis F, Goldberg I, Bell K, Tatham AJ, Ridolfi A, Hubatsch D, et al. Eur J Ophthalmol 2021;31:103–111.

This content has been developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.

